Clinical Trial Update: Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pembrolizumab in combination with carboplatin for relapsed or refractory ovarian, fallopian tube, or primary peritoneal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-07-26